《LANCET,2月5日,Reducing mortality from 2019-nCoV: host-directed therapies should be an option》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-02-07
  • Reducing mortality from 2019-nCoV: host-directed therapies should be an option

    Alimuddin Zumla, David S Hui, Esam I Azhar, Ziad A Memish, Markus Maeurer

    Published:February 05, 2020DOI:https://doi.org/10.1016/S0140-6736(20)30305-6

    The number of confirmed cases of the 2019 novel coronavirus (2019-nCoV) reported to WHO continues to rise worldwide.1 As with two other WHO Blueprint priority coronaviruses, SARS-CoV2 and MERS-CoV,3 2019-nCoV is lethal. As of Feb 3, 2020, 2019-nCoV has caused 362 deaths out of 17?391 confirmed cases reported to WHO.1 No specific anti-viral treatment exists. The mainstay of clinical management is largely symptomatic treatment, with organ support in intensive care for seriously ill patients. The unprecedented flurry of activity by WHO and other global public health bodies has mainly focused on preventing transmission, infection control measures, and screening of travellers. The development of vaccines has received immediate funding; however, as with SARS-CoV and MERS-CoV, support for developing treatments for 2019-nCoV that reduce mortality has not been forthcoming. There is an urgent need for focusing funding and scientific investments into advancing novel therapeutic interventions for coronavirus infections.

  • 原文来源:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30305-6/fulltext
相关报告
  • 《LANCET,2月6日,2019-nCoV transmission through the ocular surface must not be ignored》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-02-07
    • 2019-nCoV transmission through the ocular surface must not be ignored Cheng-wei Lu,Xiu-fen Liu,Zhi-fang Jia Published:February 06, 2020 DOI:https://doi.org/10.1016/S0140-6736(20)30313-5 Chaolin Huang and colleagues1 reported the epidemiology, symptoms, and treatment of patients infected by the 2019 novel coronavirus (2019-nCoV) in Wuhan, China. As ophthalmologists, we believe that transmission of 2019-nCoV through the eyes was ignored. On Jan 22, Guangfa Wang, a member of the national expert panel on pneumonia, reported that he was infected by 2019-nCoV during the inspection in Wuhan.2 He wore an N95 mask but did not wear anything to protect his eyes. Several days before the onset of pneumonia, Wang complained of redness of the eyes. Unprotected exposure of the eyes to 2019-nCoV in the Wuhan Fever Clinic might have allowed the virus to infect the body.2 Infectious droplets and body fluids can easily contaminate the human conjunctival epithelium.3 Respiratory viruses are capable of inducing ocular complications in infected patients, which then leads to respiratory infection.4 Severe acute respiratory syndrome coronavirus (SARS-CoV) is predominantly transmitted through direct or indirect contact with mucous membranes in the eyes, mouth, or nose.5 The fact that exposed mucous membranes and unprotected eyes increased the risk of SARS-CoV transmission4 suggests that exposure of unprotected eyes to 2019-nCoV could cause acute respiratory infection. Thus, Huang and colleagues1 should have analysed conjunctival scrapings from both confirmed and suspected 2019-nCoV cases during the onset of symptoms. The respiratory tract is probably not the only transmission route for 2019-nCoV, and all ophthalmologists examining suspected cases should wear protective eyewear.
  • 《LANCET,2月7日,Pandemic potential of 2019-nCoV》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-02-09
    • Pandemic potential of 2019-nCoV Robin Thompson Published:February 07, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30068-2 An important determinant of whether or not 2019 novel coronavirus (2019-nCoV) will ultimately cause a global pandemic is its ability to become established upon its importation to a new country. Cases of 2019-nCoV infection have so far been reported in 24 countries, yet little human-to-human transmission outside of China has occurred.